NewTimeSpace News: On 27 August 2026, IMMUNEONCO-B (01541.HK) announced that the first patient has been dosed in the Phase II trial (IMM2510-HCC-201) of IMM2510 plus IMM27M as first-line treatment for advanced HCC; the Phase Ib trial has determined the RP2D with expansion studies in esophageal squamous cell carcinoma and other solid tumors, and 6 evaluable patients in dose escalation achieved an ORR of 50%; the combination achieves synergistic coverage of PD-L1, VEGF and CTLA-4, with a Rule 18A.05 warning statement included.
NewTimeSpace News: On 27 August 2026, FOSUN PHARMA (02196.HK) announced that GR1803 injection (weliteitumab injection; trade name Weikenuo), licensed by its controlling subsidiary Yaoyou Pharmaceutical, has been granted conditional NMPA approval for adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy; the drug is a BCMA×CD3 bispecific antibody in a 20mg (2ml) per vial specification classified as Class 1 therapeutic biologics, with global sales of same-target drugs reaching approximately USD 1.139 billion in 2025, and an MAH transfer will subsequently be advanced.
NewTimeSpace News: On 27 August 2026, SSY GROUP (02005.HK) announced that it has obtained NMPA production registration approvals for gadobutrol injection (7.5ml: 4.5354g, Category 4 chemical drug) and indocyanine green for injection (25mg, Category 3 chemical drug), both deemed to have passed consistency evaluation; the products are used for contrast-enhanced MRI examinations and the diagnosis of liver diseases respectively, and together with the Group's already-registered APIs complete its integrated layout, supporting expansion into the medical imaging and critical care markets.
NewTimeSpace News: On 27 August 2026, LIVZON PHARMA (01513.HK) announced that its controlling subsidiary has received the NMPA Drug Registration Certificate for lecankitug injection (subcutaneous injection), with approval number Guoyao Zhunzi S20260065 valid until 24 August 2031; the drug is China's first independently developed IL-17A/F dual-target biologic for adult patients with moderate-to-severe plaque psoriasis, with Phase III data showing superiority over secukinumab control in onset of action, lesion clearance and long-term efficacy, and cumulative R&D investment of approximately RMB 223.31 million.
NewTimeSpace News: On 27 August 2026, CSPC PHARMA (01093.HK) announced that its SYH2092 injection, an amylin receptor agonist, has been approved by the NMPA to conduct clinical trials in China; preclinical studies showed higher target agonistic activity, significant weight loss effects and durable maintenance versus multiple amylin analogues in development, with synergistic weight loss when combined with the Group's GLP-1/GIP receptor dual biased agonist, potentially benefiting weight management in obesity and glycemic control in adult T2DM patients.
On August 27, 2026, the three major Hong Kong stock indices weakened amid volatility, while AI concept stocks were active on the day, with the large-model and AI chip sectors strengthening. The Hang Seng Index fell 0.34%, the Hang Seng TECH Index fell 0.13%, and the Hang Seng China Enterprises Index fell 0.51%.In the AI chip segment, all names rose, buoyed by NVIDIA's better-than-expected third-quarter guidance. MONTAGE TECHNOLOGY (06809.HK) rose 12.30%, ILUVATAR COREX (09903.HK) rose 10.54%, and GIGADEVICE, HUA HONG GRACE, SMIC, and BIREN TECH followed the gains.
NewTimeSpace News: On August 27, 2026, XPeng‑W (09868.HK) weakened in afternoon trading. As of 15:11, the stock traded at HKD45.12, down 3.34%.
NewTimeSpace (newtimespace.com) News, on August 27, 2026, the chip theme continued to strengthen, with HUA HONG GRACE (01347.HK) rising in choppy trade. As of 13:39, the stock was quoted at HKD 121.600, up 3.49%.
NewTimeSpace (newtimespace.com) News, on August 27, 2026, the robotics theme fluctuated higher, with MIDEA GROUP (00300.HK) weakening. As of 13:21, the stock was quoted at HKD 85.62, down 0.89%.
NewTimeSpace News: Micot announced on August 26 that the Phase‑II clinical trial of MT200605 for acute ischemic stroke has been completed. Results showed that the proportion of patients with mRS ≤1 in the high‑dose cohort was significantly higher than that in the placebo group, and the incidence of acute kidney injury (AKI) in the high‑dose cohort decreased by more than 80% versus the placebo group.
NewTimeSpace News: On 26 August 2026, BOAN BIOTECH (06955.HK) announced that the IND application for BA2201, a long-acting bispecific antibody targeting TL1A and IL-23 independently developed by the Company, has been accepted by the CDE for the treatment of IBD including Crohn's disease and ulcerative colitis, expected to become one of the first TL1A/IL-23 bispecific antibodies to enter clinical stage in China; preclinical data showed superior efficacy compared with TL1A or IL-23 monotherapy.
NewTimeSpace News: On 26 August 2026, CANSINOBIO (06185.HK) announced that its mRNA platform is advancing the development of therapeutic biological products and delivery systems, with mRNA vaccines for glioblastoma, rhabdomyosarcoma, cervical cancer and In Vivo CAR-related therapies all at an early stage; its subsidiary CanSino Shanghai has entered into a strategic cooperation framework agreement with Depushi (Hangzhou) Biotechnology for the co-development of mRNA personalized therapeutic tumor vaccines.
NewTimeSpace News: On 26 August 2026, CSPC PHARMA (01093.HK) announced that its first-in-class PD-1/IL-15 bispecific fusion protein SYS6090 (JMT108) has been granted Fast Track designation by the US FDA for the treatment of MSS/pMMR metastatic colorectal cancer (mCRC) that has progressed after prior standard systemic therapy; the product has the potential to selectively remodel the immunologically "cold" tumor microenvironment and activate exhausted effector cells.
NewTimeSpace News: On 26 August 2026, CSPC PHARMA (01093.HK) announced that its EGFR-targeting ADC SYS6010 has met the pre-specified primary endpoint of progression-free survival (PFS) in the Phase III study SYNSTAR-01 in EGFR-mutant locally advanced or metastatic NSCLC after EGFR TKI failure, as assessed by the IDMC, with PFS significantly superior to platinum-based chemotherapy with statistical significance and clinical meaningfulness, an observed trend of overall survival benefit, and a favorable overall safety profile.
On August 26, 2026, the three major indices rebounded in tandem, with AI concept stocks mostly rising more than falling that day. The Hang Seng Index (HSI) rose 0.56%, the Hang Seng TECH Index rose 0.82%, and the Hang Seng China Enterprises Index rose 1.05%.The AI chip segment diverged. HUA HONG GRACE (01347.HK) rose 6.43%, with BIREN TECH, SMIC, and MONTAGE TECHNOLOGY following the gains, while GIGADEVICE fell 2.47% and ILUVATAR COREX followed the losses.
NewTimeSpace News: On August 26, 2026, BIDU-SW (09888.HK) edged higher in the afternoon session. As of 15:03, it traded at HK$91.25, up 1.67%.
